Abstract:Importance: Colorectal cancer (CRC) screening reduces CRC incidence and mortality. It is important to examine screening patterns over time, including after the introduction of new screening modalities. Objective: To compare use of CRC screening tests before and after the availability of the multitarget stool DNA (mt-sDNA) test, given that endorsed options have changed. Design, setting, and participants: This longitudinal cohort study used administrative claims data to examine CRC screening use in 2 discrete periods: before (August 1, 2011, to July 31, 2014) and after (August 1, 2016, to July 31, 2019) the mt-sDNA test became available. The MarketScan Commercial and Medicare Supplemental databases were queried for individuals aged 45 to 75 years between August 1, 2011, and July 31, 2019, with average risk of CRC and with continuous enrollment in the databases from August 1, 2001, to July 31, 2019. Main outcomes and measures: The proportion of individuals up to date or not due for CRC screening during each measurement year and the type of screening test used among individuals due for screening. Data were reported overall and among individuals aged 45 to 49 or 50 years and older on August 1, 2011. Results: A total of 97 776 individuals with average risk were identified. Individuals had a mean (SD) age of 50.8 (3.5) years, and 54 227 (55.5%) were women. The proportion of individuals with average risk aged 50 to 75 years with commercial or Medicare supplemental insurance who were up to date with CRC screening increased from 50.4% in 2011 (30 605 of 60 770) to 69.7% in 2019 (42 367 of 60 770). Among individuals due for screening and screened, the use of high-sensitivity fecal occult blood test (FOBT) decreased between 2011 (1088 of 6241 eligible individuals [17.7%]) and 2019 (195 of 2943 eligible individuals [6.6%]), and the use of mt-sDNA increased between 2016 (58 of 3014 eligible individuals [1.9%]) and 2019 (418 of 2943 eligible individuals [14.2%]). No consistent trends were observed with fecal immunochemical test (FIT) or screening colonoscopy. Computed tomography colonography, double-contrast barium enema, and flexible sigmoidoscopy were rarely performed. Conclusions and relevance: In this cohort study, the proportion of individuals with average risk who were up to date with CRC screening increased between 2011 and 2019 but remained suboptimal. There were no substantial changes in the use of the colonoscopy or FIT; however, there was an increase in the adoption of mt-sDNA and a decrease in the use of FOBT during the study period.

S427 Cross-Sectional Adherence With the Multi-Target Stool DNA Test for Colorectal Cancer Screening Among Four Largest Payors in the Country

Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients

The impact of multi-target stool DNA testing in clinical practice in the United States: A real-world evidence retrospective study

Evaluating Outreach Methods for Multi-Target Stool DNA Test for Colorectal Cancer Screening Among an Employer Population

Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries

Clinical, social, and economic impacts of colorectal cancer screening with the multi-target stool-DNA test: 10-year experience - a simulated study

A novel multitarget stool DNA test for colorectal cancer screening

Cost-Effectiveness of Outreach Strategies for Stool-Based Colorectal Cancer Screening in a Medicaid Population

Utilization of a Colorectal Cancer Screening Test Among Individuals With Average Risk

Patient-Provider Communication and Colorectal Cancer Screening Completion Using Multi-target Stool DNA Testing

S457 Next Generation mt-sDNA Has the Best Balance Between the Benefit and Burden of the Age- and Interval-Recommended CRC Screening Among Stool- and Blood-Based Tests

Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening

Inappropriate Ordering of Multitarget Stool DNA Tests for Colon Cancer Screening

Next-generation multi-target stool DNA panel accurately detects colorectal cancer and advanced precancerous lesions

The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy

S375 Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk

Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening

Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population

Colorectal cancer screening completion: An examination of differences by screening modality

Multitarget Stool DNA Test Compared with Fecal Occult Blood Test for Colorectal Cancer Screening